Genitourinary Cancers | Topics

 
Nivolumab Granted Priority Review as Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma
April 30, 2021

Based on results of the recently reported phase 3 CheckMate 274 trial, the FDA has granted priority review designation to nivolumab for the adjuvant treatment of high-risk muscle-invasive bladder cancer.

ODAC Decision Means Atezolizumab Will Maintain It’s Indication for Frontline Urothelial Carcinoma
April 29, 2021

Accelerated approval for atezolizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for certain chemotherapy regimens was maintained by an FDA committee vote.

New Potential Frontline Standards for RCC Are Spotlighted at Genitourinary Cancers Symposium
April 25, 2021

ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.